NIA IMPACT ADVISORS, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.

Quarter-by-quarter ownership
NIA IMPACT ADVISORS, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q1 2023$254,213
-23.9%
5,620
-31.6%
0.14%
-29.4%
Q4 2022$334,074
-60.3%
8,218
-36.2%
0.19%
-62.6%
Q3 2022$842,000
-69.2%
12,878
-71.4%
0.52%
-68.4%
Q2 2022$2,737,000
-45.6%
45,036
-43.8%
1.64%
-32.6%
Q1 2022$5,027,000
+29.7%
80,082
+27.9%
2.44%
+18.6%
Q4 2021$3,876,000
-42.8%
62,609
+3.5%
2.06%
-28.8%
Q3 2021$6,772,000
+4.9%
60,499
+51.7%
2.89%
-8.3%
Q2 2021$6,458,000
+39.9%
39,891
+5.3%
3.15%
+26.2%
Q1 2021$4,617,000
-29.1%
37,892
+13.2%
2.50%
-26.4%
Q4 2020$6,509,00033,4803.39%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2021
NameSharesValueWeighting ↓
Versant Venture Management, LLC 3,608,874$160,053,562,00054.44%
Abingworth LLP 1,237,202$54,858,00032.62%
NEA Management Company, LLC 2,090,678$92,722,0004.00%
New Leaf Venture Partners, L.L.C. 444,708$19,723,0003.59%
EcoR1 Capital, LLC 500,000$22,175,0002.00%
ARK Investment Management 1,453,590$64,467,0001.95%
CLOUGH CAPITAL PARTNERS L P 337,731$14,978,0001.41%
Casdin Capital, LLC 220,000$9,757,0001.19%
Valiant Capital Management, L.P. 271,700$12,050,0001.07%
Monashee Investment Management LLC 110,000$4,879,0001.03%
View complete list of CRISPR THERAPEUTICS AG shareholders